Is it too late to buy Avacta shares?

Avacta shares have surged this year, but could the stock have a growth potential left after its recent market-smashing performance? It looks likely.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

As the rest of the stock market crashed at the end of March, Avacta (LSE: AVCT) shares surged as investors rushed to buy part of this growth story. Indeed, since the beginning of the year, shares in the company have risen by more than 700%.

And the company’s growth may be only just getting started.

Avacta shares: Positive newsflow

Avacta shares took off at the beginning of April when the company announced that it had entered into an agreement with Cytiva. The two organisations agreed to work together to manufacture an “affimer-based point-of-care rapid test” for coronavirus.

At the end of April, management provided a further update on this partnership. It informed investors the programme was running ahead of schedule, and Avacta was making good progress on the development of the test.

The organisation also revealed it owned all of the intellectual property and commercial rights to the test. It was in discussions with several other global diagnostic companies to increase production.

Since then, the company has announced further positive updates. The most recent of which was a distribution agreement with Medusa19 Limited for direct-to-consumer sales of a saliva-based rapid test for the Covid-19 antigen. Avacta shares reacted positively to this update. 

Clearly, the demand for these tests is high. Government’s around the world are pinning their hopes on mass testing regimes to get countries back to work after the coronavirus crisis. They’re going to need a massive and continuous supply of tests to do that.

Avacta is just one of the hundreds of companies developing tests for this market.

Other products

Unfortunately, it’s difficult to tell at this stage if the tests will produce a substantial earnings stream and help Avacta shares. The company has a big market, but many other corporations are competing for the same market share.

But the coronavirus tests aren’t the only strings on Avacta’s bow. Last year, the biotherapeutics business signed several large agreements with significant partners.

One of these was a therapeutics development partnership and licensing agreement with LG Chem Life Sciences. Management thinks this deal could generate potential revenues of up to $310m plus royalty payments on future product sales.

However, despite these positive developments, the firm remains loss-making. This makes it challenging to value Avacta shares.

Until we have some more clarity on future deals, as well as testing sales, it’s going to remain difficult to estimate how much the company should be worth.

That said, it’s clear Avacta has enormous potential. As such, it might be worth snapping up a few shares to hold in your portfolio as a high-risk investment.

Owning the company as part of a well-diversified portfolio would allow you to benefit from any potential upside while minimising risk.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves does not own any share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 things that could push the Lloyds share price to 60p and beyond

The Lloyds share price has broken through 50p. Next step 60p? And then what? Here are some thoughts on what…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

£1,000 in Rolls-Royce shares a year ago would be worth this much now

Rolls-Royce shares have posted one of the best stock market gains of the past 12 months. But what might the…

Read more »